A few days ago, we took a look at some of the larger
pharmaceutical companies that had begun to pullback in bull market
"3 Drug Stocks for Active Investors"
). In today's column, we turn to the retail end of the
First up is
), which has been trading in oversold territory for the past two
days after pulling back from new, 52-week highs days ago. Trading
off its lowest levels on Friday, the stock is still at significant,
short-term closing lows despite finishing fractionally higher over
the past two sessions.
CVS has a 7 out of 10 rating, putting the stock at the upper
boundary of the neutral range, but a very modest positive edge
ahead of trading on Monday. This, and the stock's proximity to
longer-term highs, suggest that CVS may have further to fall before
becoming attractive enough to lure buyers into being more
aggressive than they have been in recent days.
Almost in another world entirely - at least in terms of the
stock - is CVS rival,
). Shares of Walgreen have been toiling away below the 200-day
moving average for months, ever since slipping into bear market
territory in the summer of 2011. Rangebound since October, WAG most
recently attempted to breakout above that range earlier this week.
closes brought out the sellers, and the stock instead sold off into
The true gem among the drug store stocks over the next few days
may instead be
). Having rallied to new, 52-week high highs a week ago, shares of
GNC have been experiencing aggressive profit-taking that has sent
the stock lower by more than 10% over the past four days.
Heading into trading on Friday, GNC is set to open with a
positive edge in the short-term of three quarters of a percent.
And although trading at less than $2 per share, shares of
) are worth noting if for no other reason than the fact that they
are trading at near, 52-week highs after climbing back into
bull market territory
in early November. Up four out of the past six sessions, RAD has a
neutral rating of 4 out of 10, and could see a significant ratings
downgrade to our "consider avoiding" territory if the stock
continues to press toward overbought levels.
Be sure to read our latest column from
7 Stocks You Need to Know
Marvell Makes Good: Nearly 9% in Less Than a
is Editor in Chief of TradingMarkets.com.